Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CAM-101

Phase 3Small molecule

CCambium Bio Limited

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moderate to Severe Dry EyeNot yet recruiting

Moderate to Severe Dry EyePhase 3

Not yet recruiting

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Moderate to Severe Dry Eye

NCT06903611

Clinical

Trials by Indication[1]

Moderate to Severe Dry Eye1 trial

Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye

Not yet recruiting·CCambium Bio Limited·Phase 3·NCT06903611·400 enrolled

Dry Eye1 trial

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

Completed·CCambium Bio Limited·Phase 1/2·NCT03414645·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CAM-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAM-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAM-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cambium Bio Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCambium Bio Limited

Related News